NCT04252417View on ClinicalTrials.gov

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 11, 2019

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions
Healthy VolunteersHepatic Impairment of Moderate Child Pugh Category
Interventions
DRUG

MD1003

Single oral dose administration of MD1003 at Day 1

Trial Locations (3)

3528

Clinical Research Units Hungary Ltd., Miskolc

8231

DRC Drug Research Center Ltd., Balatonfüred

38610

Eurofins Optimed, Gières

Sponsors
All Listed Sponsors
collaborator

Eurofins Optimed

INDUSTRY

lead

MedDay Pharmaceuticals SA

INDUSTRY

NCT04252417 - HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects | Biotech Hunter | Biotech Hunter